Japanese Legislation for Accelerating Drug Development

Watch our free webinar to learn about the new legislations introduced by Japan’s Health Ministry, which aim to support fast-track opportunities for orphan and innovative drugs for UK companies in Japan’s pharmaceuticals market.

As one of the largest global pharmaceutical markets, Japan’s regulatory authority, Pharmaceuticals and Medical Devices Agency (PMDA) introduced several new legislations for accelerating drug development. Dr Gemba from Integrated Development Associates Co Ltd (IDA) will introduce the following three key legislations and how to utilise them for fast approval and access to Japan’s pharmaceutical market.

This content has been restricted to logged in users only. Please login to view this content.

The remainder of this article is a resource for members only. Please register or login to access. 

Get free and unlimited access to in-depth market reports, videos, invitations to relevant events and priority support. Join here.

Contact Kaori and her expert team to learn more about the life sciences market in Japan.

This webinar was recorded on 18 November 2015.

Japanese Legislation for Accelerating Drug Development Webinar Slides